Recent Ozempic, Victoza data ‘promising’ for diabetic kidney disease
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk talks exclusively to PharmaTimes.
Read More
Tag: SOUL trial
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
